Elusys Awarded Additional $40.6 Million Under Exisiting US Government Contract To Fund Advanced Development Of Anthim, A New Treatment For Anthrax

Media Center PRESS RELEASE 2010 ELUSYS AWARDED ADDITIONAL $40.6 MILLION UNDER EXISITING US GOVERNMENT CONTRACT TO FUND ADVANCED DEVELOPMENT OF ANTHIM, A NEW TREATMENT FOR ANTHRAX Funding awarded by BARDA (Biomedical Advanced Research & Development Authority); Anthim being developed to treat inhaled anthrax, one of the top bioterrorism threats Pine Brook, NJ – August 4, […]

Elusys Therapeutics and Lonza Extend Manufacturing Agreement For Anthim, a New Anthrax Treatment In Late-Stage Development

Media Center PRESS RELEASE 2010 ELUSYS THERAPEUTICS AND LONZA EXTEND MANUFACTURING AGREEMENT FOR ANTHIM, A NEW ANTHRAX TREATMENT IN LATE-STAGE DEVELOPMENT Pine Brook, NJ (USA) and Basel (Switzerland), 15 July 2010 – Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development […]

Elusys Receives Contract for up to $143 Million from the US Federal Government to Fund Advanced Development of Anthim®, a New Treatment for Anthrax

Media Center PRESS RELEASE 2010 ELUSYS RECEIVES CONTRACT FOR UP TO $143 MILLION FROM THE US FEDERAL GOVERNMENT TO FUND ADVANCED DEVELOPMENT OF ANTHIM®, A NEW TREATMENT FOR ANTHRAX Funding awarded by BARDA (Biomedical Advanced Research & Development Authority); Anthim being developed to treat inhaled anthrax, one of the top bioterrorism threats Pine Brook, NJ […]